Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Does CheckMate 026 Take Bristol Out Of The End Game?

Aug 06 2016

• By Emily Hayes

chess

Related Content

Merck Is Finding PD-L1 Testing Is Helping Keytruda

May 06 2016

Bristol Should Have Opdivo First-Line Lung Cancer Data In Weeks

Jul 29 2016

Merck Defends Its Offensive Strategy For Keytruda

Jul 30 2016

Merck Oncology Strategy: With First-Line Lung Data, A New Day Dawns For Keytruda

Jun 27 2016

Bristol's Oncology Strategy: Cover All The Bases To Keep The Lead

Jul 04 2016

Related Companies

Bristol Myers Squibb Company

Merck & Co., Inc.

AstraZeneca PLC

Roche Holding AG

Additional Topics

Clinical Trials Research & Development Commercial Companies Strategy Cancer BioPharmaceutical

More from Anticancer

More from Therapy Areas

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window